Designed for Precision.
Developed for Life.

At Adcendo, we are developing a new generation of antibody-drug conjugates (ADCs) using a target and indication-driven approach to address cancers with high unmet medical need.

 

Our programs are designed from the outset to achieve the best possible balance of efficacy and tolerability, with the potential to deliver meaningful benefit for patients worldwide.

Latest News